Danaher (NYSE:DHR) Price Target Raised to $260.00

Posted by Francis Steltz on Oct 25th, 2026

Danaher (NYSE:DHR – Free Report) had its price target boosted by Stifel Nicolaus from $220.00 to $260.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the conglomerate’s stock.

Several other brokerages have also recently weighed in on DHR. TD Cowen boosted their price target on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada increased their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. UBS Group began coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $242.91.

Read Our Latest Stock Report on Danaher

Danaher Stock Performance

NYSE DHR opened at $230.36 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.25. Danaher has a 1-year low of $160.93 and a 1-year high of $242.80. The business has a 50 day simple moving average of $216.32 and a two-hundred day simple moving average of $197.35. The stock has a market capitalization of $162.07 billion, a PE ratio of 37.70, a P/E/G ratio of 2.88 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.89 EPS. On average, research analysts predict that Danaher will post 8.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is 26.19%.

Institutional Investors Weigh In On Danaher

Several hedge funds and other institutional investors have recently made changes to their positions in DHR. BlackRock Inc. bought a new position in Danaher during the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP lifted its stake in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC bought a new stake in Danaher in the second quarter worth about $1,456,317,000. Generation Investment Management LLP purchased a new position in shares of Danaher during the second quarter valued at approximately $1,287,949,000. Finally, Bank of America Corp DE purchased a new position in shares of Danaher during the second quarter valued at approximately $993,846,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

About Danaher

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.